Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOY-101 in Advanced Non-Neovascular AMD
NCT05380492Phase 2Active, not recruiting
- Sponsor
- Perceive Biotherapeutics
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of VOY-101 in geographic atrophy (GA), sponsored by Perceive Biotherapeutics. Primary endpoint: Safety Endpoints at 24 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
VOY-101
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT05380492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380492.